C1q activators constitute a diverse array of chemical entities that are characterized by their ability to enhance the functional activity of the C1q protein, a key component of the classical complement pathway. C1q is primarily recognized for its role in the immune system where it binds to the Fc region of antibodies that are attached to pathogens, triggering a series of immune responses that include the opsonization of pathogens and the initiation of a complement cascade resulting in the formation of a membrane attack complex. Activators of C1q can operate through various mechanisms, with some directly binding to the C1q molecule itself, thereby stabilizing its conformation and enhancing its ability to initiate the complement cascade. Others may work by upregulating the cellular pathways that lead to the expression and stabilization of C1q or its receptor interactions, which are essential for its proper functioning in the immune response. These chemicals, while diverse in structure, share the common feature of promoting the activity of C1q without necessarily increasing its expression.
The biochemical activation mechanisms of C1q activators can be quite intricate. Some activators may influence the configuration of C1q, facilitating its interaction with the C1r2s2 complex, which is a crucial step in the activation of the classical pathway. Other compounds may interact with various regulators of complement activation, such as C1 inhibitor (C1-INH), to sustain a favorable balance that promotes C1q function. By influencing the proteases that cleave and activate downstream components of the complement system, such as C4 and C2, these activators indirectly bolster the function of C1q. Although they do not directly modify the protein structure of C1q, their actions on related molecules and signaling pathways result in a net increase in the functional potential of C1q, thus enhancing its role in the immune system's defense mechanisms. Collectively, these activators work in concert to ensure that C1q can effectively fulfill its role in the recognition and clearance of pathogens, as well as in the removal of apoptotic cells, thereby maintaining homeostasis within the immune system.
製品名 | CAS # | カタログ # | 数量 | 価格 | 引用文献 | レーティング |
---|---|---|---|---|---|---|
Suberoylanilide Hydroxamic Acid | 149647-78-9 | sc-220139 sc-220139A | 100 mg 500 mg | $130.00 $270.00 | 37 | |
ヒストン脱アセチル化酵素阻害剤は、C1q発現のエピジェネティックな制御を変化させ、その活性を変化させる可能性がある。 | ||||||
MCC950 sodium salt | 256373-96-3 | sc-505904 sc-505904A sc-505904B sc-505904C | 5 mg 10 mg 50 mg 100 mg | $112.00 $194.00 $871.00 $1538.00 | 3 | |
MCC950のような化合物はNLRP3インフラマソームを阻害し、C1qを含む補体活性化に下流から影響を及ぼす可能性がある。 | ||||||
BAY 11-7082 | 19542-67-7 | sc-200615B sc-200615 sc-200615A | 5 mg 10 mg 50 mg | $61.00 $83.00 $349.00 | 155 | |
NF-kBを阻害するBAY 11-7082のような化合物は、C1qを含む補体系遺伝子の転写に影響を与えるかもしれない。 | ||||||
Rosiglitazone | 122320-73-4 | sc-202795 sc-202795A sc-202795C sc-202795D sc-202795B | 25 mg 100 mg 500 mg 1 g 5 g | $118.00 $320.00 $622.00 $928.00 $1234.00 | 38 | |
PPARγアゴニストはマクロファージ機能を調節し、間接的にC1q活性に影響を与える可能性がある。 | ||||||
FTY720 | 162359-56-0 | sc-202161 sc-202161A sc-202161B | 1 mg 5 mg 25 mg | $32.00 $75.00 $118.00 | 14 | |
スフィンゴシン-1-リン酸受容体モジュレーターは、リンパ球の脱出と機能に影響を与え、C1q活性に下流で影響を与える可能性がある。 | ||||||
SB 431542 | 301836-41-9 | sc-204265 sc-204265A sc-204265B | 1 mg 10 mg 25 mg | $80.00 $212.00 $408.00 | 48 | |
SB431542と他のTGF-β経路阻害剤は、C1qを含む補体成分の発現に影響を与える可能性がある。 | ||||||
BMS-345541 | 445430-58-0 | sc-221741 | 1 mg | $306.00 | 1 | |
IKKを阻害する化合物は、NF-kBシグナル伝達に影響を与え、それによってC1qの発現に影響を与える可能性がある。 |